South Africa Biosimilars Market Size & Outlook, 2026-2033
Global Market
Related Markets
South Africa biosimilars market highlights
- The South Africa biosimilars market generated a revenue of USD 90.6 thousand in 2025 and is expected to reach USD 363.3 thousand by 2033.
- The South Africa market is expected to grow at a CAGR of 19.1% from 2026 to 2033.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating drug class in 2025.
- Insulin & Analogues is the most lucrative drug class segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2025 | USD 90.6 thousand |
| Market revenue in 2033 | USD 363.3 thousand |
| Growth rate | 19.1% (CAGR from 2026 to 2033) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Insulin & Analogues |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD thousand |
| Market segmentation | Monoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents, Insulin & Analogues, Osteoporosis / Bone Metabolism Agents, Others Drug Class |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.2% of the global biosimilars market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Middle East & Africa, Saudi Arabia biosimilars market is projected to lead the regional market in terms of revenue in 2033.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 282.9 thousand by 2033.
Increase in product approvals is anticipated to boost market growth in the near future. For instance, in August 2018, Teva Pharmaceuticals and Cipla collaborated to launch South Africa’s first biosimilar, Filgrastim.
This biosimilar—manufactured by Teva & marketed by Cipla in the country—is indicated for chemotherapy-induced neutropenia. The introduction of filgrastim in South Africa was expected to reduce the cost of neutropenia treatment.
According to a study published in The Lancet, by 2030, there is estimated to be an 85% increase in the number of cancer cases in sub-Saharan Africa. Therefore, increase in product approvals is expected to fuel South Africa’s adoption of biosimilars over the forecast period.
No credit card required*
Publish Date: Nov 05, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Dr. Reddy’s Laboratories | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | www.drreddys.com/ |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
| Samsung Bioepis | View profile | 501-1000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbioepis.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | www.biocon.com |
South Africa Biosimilars Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimilars Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies (Mabs) was the largest segment with a revenue share of 52.87% in 2025.
Horizon Databook has segmented the South Africa biosimilars market based on monoclonal antibodies (mabs), growth factors & hematopoietic agents, insulin & analogues, osteoporosis / bone metabolism agents, others drug class covering the revenue growth of each sub-segment from 2021 to 2033.
Increase in product approvals is anticipated to boost market growth in the near future. For instance, in August 2018, Teva Pharmaceuticals and Cipla collaborated to launch South Africa’s first biosimilar, Filgrastim.
This biosimilar—manufactured by Teva & marketed by Cipla in the country—is indicated for chemotherapy-induced neutropenia. The introduction of filgrastim in South Africa was expected to reduce the cost of neutropenia treatment.
According to a study published in The Lancet, by 2030, there is estimated to be an 85% increase in the number of cancer cases in sub-Saharan Africa. Therefore, increase in product approvals is expected to fuel South Africa’s adoption of biosimilars over the forecast period.
- South Africa Biosimilars Market Drug Class Outlook (Revenue, USD Thousand , 2021-2033)
- Monoclonal Antibodies (mAbs)
- Growth Factors & Hematopoietic Agents
- Insulin & Analogues
- Osteoporosis / Bone Metabolism Agents
- Others
- South Africa Biosimilars Market Indication Outlook (Revenue, USD Thousand , 2021-2033)
- Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
- Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
- Diabetes Mellitus (Type 1 & Type 2)
- Ophthalmic Disorders (Wet AMD, DME, RVO)
- Hematologic / Rare Blood Disorders
- Others
- South Africa Biosimilars Market End Use Outlook (Revenue, USD Thousand , 2021-2033)
- Hospitals
- Specialty Pharmacies
- Online & Retail Channels
Reasons to subscribe to Biosimilars Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biosimilars Market Outlook databook
- Our clientele includes a mix of Biosimilars Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa Biosimilars Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Africa Biosimilars Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
South Africa Biosimilars Market, 2021-2033 (US$K)
South Africa biosimilars market statistics, by drug class, 2021-2033 (USD Thousand)
